Key facts: TXG Q2 $151M,-$17.9M;Citigroup PT $50;Morgan Stanley neutral
10x Genomics (TXG) reported Q2 2026 revenue of $151.0M and a net loss of $17.9M, with diluted EPS of -$0.14, versus Q2 2025 revenue of $172.9M and net income of $34.5M (EPS $0.28). Citigroup maintained a Neutral rating and raised its price target to $50. Morgan Stanley kept Neutral/Equal-Weight.
How this was made
The 30-second read
Why it matters
Traders may use the PT update as a sentiment input, but without new guidance or a surprise datapoint, the incremental impact is likely limited.
Market read
Company-specific earnings figures plus a PT raise can influence short-term positioning, but the lack of guidance or surprise limits decision value.
What to watch
The summary lacks cash flow, guidance, and segment detail, which are often the true drivers of follow-through after earnings.
Background
The article summarizes 10x Genomics Q2 2026 results and notes sell-side stance changes from Citigroup and Morgan Stanley.
Ticker impact
10x Genomics reported Q2 2026 revenue of $151.0M and net loss of $17.9M, while analysts updated targets and ratings.
Near-term trading likely modest, driven more by analyst framing than by new company fundamentals beyond the stated Q2 figures.
The article provides Q2 financial numbers and PT updates, but it does not add guidance, surprises, or a new catalyst beyond the reported quarter and analyst stance.
Market effects
Limited read-through to biotech/genomics peers because the piece is primarily company-specific and lacks sector-wide regulatory or demand signals.
No clear regional spillover described; focus remains on US-listed TXG and US sell-side actions.
No global macro or international transaction details provided.
Counterpoint
Despite the raised Citigroup target, both major banks cited remain Neutral, suggesting the market may already be pricing the quarter and the PT change may not shift expectations materially.
Key entities
- company10x Genomics
Reported Q2 2026 revenue of $151.0M and net loss of $17.9M; analysts updated price target and maintained Neutral ratings.
- analyst_firmCitigroup
Kept Neutral on TXG and raised its price target to $50.
- analyst_firmMorgan Stanley
Kept Neutral/Equal-Weight on TXG.
